Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
azacitidine
- Development stage
- Approved
- Lead developer
- Bristol Myers Squibb
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Administration
- Subcutaneous, Intravenous, Oral
01
Overview
Azacitidine is a pyrimidine nucleoside analogue and antimetabolite chemotherapy drug used primarily for the treatment of myelodysplastic syndromes (MDS), acute myeloid leukemia (AML), chronic myelomonocytic leukemia (CMML), and juvenile myelomonocytic leukemia (JMML). It acts as a chemical analog of cytidine and exerts its antineoplastic effects through two main mechanisms. At low doses, it inhibits DNA methyltransferase enzymes, leading to hypomethylation of DNA and reactivation of silenced genes. At higher doses, it incorporates into RNA and DNA, disrupting their metabolism and synthesis—resulting in cytotoxicity to abnormal hematopoietic cells. Azacitidine is administered either by subcutaneous or intravenous injection or as an oral tablet. The drug was originally developed by Pharmacia & Upjohn.
- Brand names
- VidazaOnureg
- Other names
- 5-azacytidine5-azaCazacytidine
02
Targets
DNMT1 (DNA (cytosine-5)-methyltransferase 1)TRDMT1 (DNA methyltransferase 2)
Beyond the preview
Go deeper on azacitidine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on azacitidine.